Infervision vs Lunit
Lunit's chest X-ray product, INSIGHT CXR Triage, is K211733 of November 10, 2021, code QFM. Infervision's six openFDA records are lung nodule CT (K192880 of July 2, 2020 and K240554 of May 16, 2025), head CT triage, surgical planning and RECIST software, and none is named for InferRead DR Chest. A US hospital buying chest X-ray AI starts from a cleared triage product with Lunit and from none with Infervision.
Each vendor points its chest X-ray tool at TB screening. Lunit's timeline says the WHO recommended it for that use, and a 2025 independent comparison in PLOS Digital Health found a newer INSIGHT CXR version less accurate until its threshold was recalibrated.
A lung nodule program reading CT is Infervision's customer, with follow-up registration and volume doubling time in InferRead Lung CT.AI. A breast screening service is Lunit's, using INSIGHT MMG, DBT and the Volpara density tools, bought in 2024 for about US$193M by Radiology Business's figure.
Radiology · Reviewed November 2, 2026
Infervision
by Infervision · founded 2016
AI for CT lung nodules, CT stroke, surgical planning and RECIST follow-up, with FDA clearances for these CT products.
Lunit
by Lunit · founded 2013
AI for chest X-ray, mammography and breast tomosynthesis, Volpara breast-density tools, and pathology biomarker software (SCOPE).
When to pick each one
Infervision
- Lung nodule CADe on CT, K192880 and K240554
- Follow-up registration with volume doubling time
Lunit
- Chest X-ray triage cleared as K211733
- Mammography and tomosynthesis AI with Volpara density tools
Score
Each row shows points earned of points available under the published rubric.
Infervision
57of 100
Lunit
66of 100
| Dimension | Infervision | Lunit | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 12.7 / 18.2 | 12.7 / 18.2 | 0 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 7.8 / 7.8 | -7.8 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 6 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
Infervision
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Lunit
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Contact form only. |
Evidence
Infervision
FDA decisions
K260973 (opens in new tab)510(k)2026-07-07
InferOperate Suite
K252261 (opens in new tab)510(k)2026-03-13
InferCare RECIST
K250237 (opens in new tab)510(k)2025-09-15
InferOperate Suite
K240554 (opens in new tab)510(k)2025-05-16
InferRead Lung CT.AI
K211179 (opens in new tab)510(k)2021-08-12
InferRead CT Stroke.AI
Show 1 more
K192880 (opens in new tab)510(k)2020-07-02
InferRead Lung CT.AI
Peer-reviewed
4 PubMed records name Infervision.
- Spatial classification of clinical T1a-bN0 non-small cell lung cancer in superior segment based on three-dimensional reconstruction: optimizing surgical margin and operative strategy. (opens in new tab)
- AI-assisted clinico-quantitative imaging nomogram for preoperative malignancy risk in solid and part-solid pulmonary nodules ≤ 3 cm: development and internal validation. (opens in new tab)
- Impact of dose reduction and iterative reconstruction algorithm on the detectability of pulmonary nodules by artificial intelligence. (opens in new tab)
Lunit
FDA decisions
K260320 (opens in new tab)510(k)2026-04-23
Lunit INSIGHT MMG (v1.1.10)
K253796 (opens in new tab)510(k)2026-03-26
Lunit INSIGHT DBT (V1.2)
K242652 (opens in new tab)510(k)2024-10-04
Lunit INSIGHT DBT v1.1
K231470 (opens in new tab)510(k)2023-11-06
Lunit INSIGHT DBT
K211678 (opens in new tab)510(k)2021-11-17
Lunit INSIGHT MMG
Show 3 more
K211733 (opens in new tab)510(k)2021-11-10
Lunit INSIGHT CXR Triage
K211279 (opens in new tab)510(k)2021-07-27
Volpara Imaging Software
K182310 (opens in new tab)510(k)2018-09-21
Volpara Imaging Software
Peer-reviewed
3 PubMed records name Lunit.
- Comparison of different Lunit INSIGHT CXR software versions when reading chest radiographs for tuberculosis. (opens in new tab)
- Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21). (opens in new tab)
- Long-term prognostic implications of AI-detected versus AI-undetected breast cancers on mammography: a propensity score-matched analysis. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Infervision | Lunit |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2016 | 2013 |
| HQ | n/a | KR |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.